Skip to content
Screener

Amgen AMGN Cash, Cash Equivalents, and Marketable Securities

Cash, Cash Equivalents, and Marketable Securities at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$15.19B
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$694.16M+280%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$348.72M+58.6%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$123.37M
Tango Therapeutics logo
Tango TherapeuticsTNGX
$154.03M+171%

Other financials

Income statement

See full
Revenue$10.1B+9.5%
Gross profit$7.2B+17.4%
Operating income$3.5B+32.3%
Net income$2.4B+65.9%
EPS (diluted)$4.37+64.9%

Balance sheet

See full
Cash & equivalents$574.0M+5.9%
Total debt$57.3B+2.0%
Total equity$11.7B+57.4%
Total assets$95.6B+8.8%

Cash flow

See full
Operating cash flow$4.0B+75.5%
CapEx$513.0M+39.0%
Free cash flow$3.5B+82.6%

Valuation

See full
Market cap$222.32B+43.3%
Enterprise value$279.05B+32.4%
P/E25.4×+2.0×
P/S5.8×+1.4×

Profitability

See full
Gross margin69.5%+5.0pp
Operating margin30%+6.5pp
Net margin23%+4.0pp
FCF margin26.7%-3.7pp

Returns & leverage

See full
Return on equity91.5%-7.7pp
Debt / equity4.9×-2.7×
Current ratio1.4×+0.1×

Where this comes from

Reported directly by Amgen in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecurities.

The source filing: Amgen’s 10-Q, filed August 5, 2026.

Filed
Aug 4, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000318154-26-000126
Types of securities as of June 30, 2026AmortizedcostGrossunrealizedgainsGrossunrealizedlossesFairvalues
U.S. Treasury bills$2,493$2,493
Money market mutual funds10,79310,793
Other short-term interest-bearing securities129129
Total interest-bearing securities$13,415$13,415

Item 1. FINANCIAL STATEMENTS

FAQ

What is Amgen's cash, cash equivalents, and marketable securities?
Amgen (AMGN) reported cash, cash equivalents, and marketable securities of $13.42B in Q2 2026.
How has Amgen's cash, cash equivalents, and marketable securities changed year-over-year?
Amgen's cash, cash equivalents, and marketable securities increased by 79.2% year-over-year, from $7.49B to $13.42B.
What is the long-term trend for Amgen's cash, cash equivalents, and marketable securities?
Over 5 years (2020 to 2025), Amgen's cash, cash equivalents, and marketable securities has grown at a -2.8% compound annual growth rate (CAGR), from $9.85B to $8.53B.
What does cash, cash equivalents, and marketable securities mean?
This represents the most liquid assets held by the company, including cash on hand, bank deposits, and short-term investments that can be readily converted into cash. It serves as the primary buffer for operational liquidity and potential capital allocation activities. Investors monitor this to assess the company's ability to meet short-term obligations and fund growth initiatives.

Ask your AI about Amgen's cash, cash equivalents, and marketable securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude